Prostatic Cancer
The most common neoplasm in males older than age 50, prostatic cancer is a leading cause of male cancer death. Adenocarcinoma is the most common form; only seldom does prostatic cancer occur
as a sarcoma. Most prostatic cancers originate in the posterior prostate gland, with the rest growing near the urethra. Malignant prostatic tumors seldom result from the benign hyperplastic enlargement that commonly develops around the prostatic urethra in older males.
as a sarcoma. Most prostatic cancers originate in the posterior prostate gland, with the rest growing near the urethra. Malignant prostatic tumors seldom result from the benign hyperplastic enlargement that commonly develops around the prostatic urethra in older males.
Slow-growing prostatic cancer seldom produces signs and symptoms until it’s well advanced. Typically, when primary prostatic lesions spread beyond the prostate gland, they invade the prostatic capsule and then spread along the ejaculatory ducts in the space between the seminal vesicles or perivesicular fascia. When prostatic cancer is fatal, death usually results from widespread bone metastases. Incidence of prostatic cancer is highest among Blacks and lowest among Asians. It appears unaffected by socioeconomic status or fertility.
Causes
The primary risk factor for prostatic cancer is age (the cancer seldom develops in males younger than age 40). Endocrine factors also have a role. Androgens are necessary for tumor growth.
Complications
Progressive disease can lead to spinal cord compression, deep vein thrombosis, and pulmonary emboli.
Assessment
The patient’s history may reveal urinary problems, such as dysuria, frequency, complete urine retention, back or hip pain, and hematuria. When the patient reports these signs and symptoms, the disease is likely to be advanced. Furthermore, back or hip pain may signal bone metastasis. The patient usually has no signs or symptoms in early disease.
Inspection may reveal edema of the scrotum or leg in advanced disease. During rectal examination, prostatic palpation may detect a nonraised, firm, nodular mass with a sharp edge (in early disease) or a hard lump (in advanced disease).
Diagnostic tests
Digital rectal examination (DRE), recommended yearly by the American Cancer Society for males older than age 40, is the standard screening test.
Blood tests may show elevated levels of prostate-specific antigen (PSA). Although most males with metastasized prostatic cancer will have an elevated PSA level, the finding also occurs with other prostatic disease. The PSA level should be assessed in light of DRE findings.
Transrectal prostatic ultrasonography may be used for patients with abnormal DRE and PSA test findings.
Bone scan and excretory urographyStay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree